Pfizer Partners with China’s 3SBio in $6 Billion Deal to Advance New Cancer Therapy

Global pharmaceutical giant Pfizer has announced a major partnership with Chinese biotech firm 3SBio Inc. to develop and market a promising new cancer drug. The agreement marks a significant step in international collaboration on cancer treatment innovation.

Under the deal, Pfizer will license the experimental therapy, known as SSGJ-707, a next-generation bispecific antibody designed to target PD-1 and VEGF—proteins commonly linked to cancer growth. This drug is currently being tested in clinical trials across China for a range of cancers, including non-small cell lung cancer, colorectal cancer, and certain gynecological tumors.

Key Details of the Deal:

• Pfizer will pay $1.25 billion upfront and could make additional payments totaling up to $4.8 billion if the drug meets development and sales milestones.

• The company will also invest $100 million in 3SBio through a strategic equity stake.

• Pfizer gains exclusive global rights to develop, produce, and commercialize the drug—excluding China, though it retains the option to expand there later.

• U.S. regulators have already approved the drug’s Investigational New Drug (IND) application, paving the way for testing in American trials.

• Manufacturing is expected to take place in North Carolina (drug substance) and Kansas (final product).

Why It Matters:

This collaboration is a bold move by Pfizer to grow its oncology pipeline and signals increasing confidence in the innovation coming out of China’s biotech sector. With a Phase III trial on the horizon, SSGJ-707 could become a global player in the fight against cancer.

Following the announcement, 3SBio’s stock soared by 35% on the Hong Kong exchange, boosting its market value to nearly $6 billion.